AssertioASRT
ASRT
About: Assertio Holdings Inc is a pharmaceutical company. It is engaged in providing solutions to advance patient care in the areas of neurology, orphan and specialty medicines. The company markets three FDA-approved products for various neurological conditions including Gralise, tablets for the management of postherpetic neuralgia; CAMBIA, for acute treatment of migraine attacks with or without aura in adults of age or older and Zipsor, liquid-filled capsules for relief of mild to moderate pain.
Employees: 30
0
Funds holding %
of 7,429 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
2,596% more call options, than puts
Call options by funds: $701K | Put options by funds: $26K
33% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 6
0% more funds holding
Funds holding: 68 [Q1] → 68 (+0) [Q2]
0.74% less ownership
Funds ownership: 26.52% [Q1] → 25.78% (-0.74%) [Q2]
6% less capital invested
Capital invested by funds: $17.1M [Q1] → $16M (-$1.1M) [Q2]
52% less repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 23
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$3
280%
upside
Avg. target
$3
280%
upside
High target
$3
280%
upside
1 analyst rating
1 positive
100%
0 neutral
0%
0 negative
0%
HC Wainwright & Co. Raghuram Selvaraju | 280%upside $3 | Buy Maintained | 12 Aug 2025 |
Financial journalist opinion
Based on 11 articles about ASRT published over the past 30 days
Negative
Zacks Investment Research
2 hours ago
New Strong Sell Stocks for August 26th
ASRT, BSM and JJSF have been added to the Zacks Rank #5 (Strong Sell) List on August 26, 2025.
Neutral
PRNewsWire
1 day ago
NASDAQ: SPPI DEADLINE REMINDER: Berger Montague Reminds Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) Investors of Important Class Action Lawsuit Deadline
PHILADELPHIA , Aug. 25, 2025 /PRNewswire/ -- National plaintiffs' law firm Berger Montague PC is investigating securities fraud claims against Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) ("Spectrum" or the "Company") on behalf of investors who purchased or otherwise acquired common shares of Spectrum between March 17, 2022 through September 22, 2022 (the "Class Period"). Investor Deadline: Investors who purchased or acquired Spectrum securities during the Class Period may, no later than September 24, 2025 , seek to be appointed as a lead plaintiff representative of the class.
Neutral
PRNewsWire
6 days ago
NASDAQ: SPPI CLASS ACTION NOTICE: Berger Montague Encourages Spectrum Pharmaceuticals (NASDAQ: SPPI) Investors to Inquire About a Securities Fraud Class Action
PHILADELPHIA , Aug. 19, 2025 /PRNewswire/ -- National plaintiffs' law firm Berger Montague PC is investigating securities fraud claims against Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) ("Spectrum" or the "Company") on behalf of investors who purchased or otherwise acquired common shares of Spectrum between March 17, 2022 through September 22, 2022 (the "Class Period"). Investor Deadline: Investors who purchased or acquired Spectrum securities during the Class Period may, no later than September 24, 2025 , seek to be appointed as a lead plaintiff representative of the class.
Neutral
GlobeNewsWire
1 week ago
SHAREHOLDER ALERT: Berger Montague Reminds Spectrum Pharmaceuticals (NASDAQ: SPPI) Investors of Class Action Lawsuit Deadline
PHILADELPHIA, Aug. 18, 2025 (GLOBE NEWSWIRE) -- National plaintiffs' law firm Berger Montague PC is investigating securities fraud claims against Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) (“Spectrum” or the “Company”) on behalf of investors who purchased or otherwise acquired common shares of Spectrum between March 17, 2022 through September 22, 2022 (the “Class Period”).
Neutral
PRNewsWire
1 week ago
NASDAQ: SPPI INVESTOR ALERT: Berger Montague Advises Spectrum Pharmaceuticals (NASDAQ: SPPI) Investors of September 24, 2025 Deadline
PHILADELPHIA , Aug. 13, 2025 /PRNewswire/ -- National plaintiffs' law firm Berger Montague PC is investigating securities fraud claims against Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) ("Spectrum" or the "Company") on behalf of investors who purchased or otherwise acquired common shares of Spectrum between March 17, 2022 through September 22, 2022 (the "Class Period"). Investor Deadline: Investors who purchased or acquired Spectrum securities during the Class Period may, no later than September 24, 2025 , seek to be appointed as a lead plaintiff representative of the class.
Neutral
Zacks Investment Research
2 weeks ago
Assertio (ASRT) Reports Q2 Loss, Beats Revenue Estimates
Assertio (ASRT) came out with a quarterly loss of $0.17 per share versus the Zacks Consensus Estimate of a loss of $0.1. This compares to a loss of $0.04 per share a year ago.
Neutral
Seeking Alpha
2 weeks ago
Assertio Holdings, Inc. (ASRT) Q2 2025 Earnings Call Transcript
Assertio Holdings, Inc. (NASDAQ:ASRT ) Q2 2025 Earnings Conference Call August 11, 2025 4:30 PM ET Company Participants Ajay Patel - Executive VP & CFO Brendan P. O'Grady - CEO & Director Conference Call Participants Nazibur Rahman - Maxim Group LLC, Research Division Raghuram Selvaraju - H.C.
Neutral
GlobeNewsWire
2 weeks ago
Assertio Reports Second Quarter 2025 Financial Results
Second Quarter Total Net Product Sales of $28.8 Million, Cash and Investments Increase to $98.2 Million Narrows Guidance on Continued Progress Implementing Long-Term Business Strategy LAKE FOREST, Ill., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated products designed to address patients' needs, today reported financial results for the second quarter ended June 30, 2025.
Neutral
GlobeNewsWire
2 weeks ago
ATTENTION NASDAQ: SPPI INVESTORS: Contact Berger Montague About a Spectrum Pharmaceuticals Class Action Lawsuit
PHILADELPHIA, Aug. 07, 2025 (GLOBE NEWSWIRE) -- National plaintiffs' law firm Berger Montague PC is investigating securities fraud claims against Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) (“Spectrum” or the “Company”) on behalf of investors who purchased or otherwise acquired common shares of Spectrum between March 17, 2022 through September 22, 2022 (the “Class Period”).
Neutral
PRNewsWire
2 weeks ago
Berger Montague PC Investigating Claims on Behalf of Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) Investors
PHILADELPHIA , Aug. 6, 2025 /PRNewswire/ -- National plaintiffs' law firm Berger Montague PC is investigating securities fraud claims against Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) ("Spectrum" or the "Company") on behalf of investors who purchased or otherwise acquired common shares of Spectrum between March 17, 2022 through September 22, 2022 (the "Class Period"). Investor Deadline: Investors who purchased or acquired Spectrum securities during the Class Period may, no later than September 24, 2025 , seek to be appointed as a lead plaintiff representative of the class.
Charts implemented using Lightweight Charts™